| abstract |
The present invention relates to a compound of formula I,nOr a pharmaceutically acceptable salt thereof, wherein - A1 is NR1 or CR1, wherein R1 is as described herein; - the cyclopropyl moiety is optionally substituted with one or more methyl groups and one or more F; - A2 To A5 are respectively N or CR2 to CR5, and no more than 2 of the 4 positions A of the conditional lines A2 to A5 may be N at the same time; - R2 to R5 are as described herein; - R6 and R7 are independently H, F, methyl, ethyl, hydroxy or methoxy or R6 and R7 together are carbonyl, all alkyl (if present) optionally substituted by one or more F; - R8 H or C (1-6) An alkyl group; - A9 to A12 are N or CR9 to CR12, respectively, and no more than 2 of the 4 positions A in the condition A9 to A12 may be N at the same time;nR9 to R12 are as described herein; - R13 and R14 are as described herein; or by R13 which is a C(1-6)alkyl or C(2-6)alkenyl group, as defined in R14 Independent substituents are joined to fuse R13 and R14 and form a ring having 5 to 7 atoms, all groups optionally passing one or more halogen, amine, hydroxyl, cyano, C(1-3) alkoxy a group, a C(1-3) alkoxycarbonyl group, a (di)C(1-3)alkylamino group or a C(1-3)alkyl group.nThese compounds are useful as inhibitors of RORy and are useful in the treatment of RORy-mediated diseases. |